Every 10-Q that CURANEX PHARMACEUTICALS INC (CURX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CURX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CURX filings page.
Curanex Pharmaceuticals Inc. reported no revenue and a substantially higher net loss of $6.44 million for the six months ended June 30, 2026, compared with $0.20 million a year earlier, driven by ramp-up in R&D and public-company costs. R&D expenses reached $4.85 million, reflecting IND-enabling work for lead botanical candidate Phyto-N and expansion into a new indication, cancer cachexia.
Cash and cash equivalents were $2.94 million at June 30, 2026, down from $4.97 million at year-end, while prepaid R&D fell sharply as prior up-front payments were utilized. The company discloses substantial doubt about its ability to continue as a going concern and expects cash needs to rise as clinical activities approach.
Curanex faces a Nasdaq minimum bid price deficiency and is implementing a 1-for-20 reverse stock split targeted to be effective by August 20, 2026, though compliance is not assured. Disclosure controls and procedures were deemed not effective, and the company plans to fund future operations through additional equity or debt, which would dilute existing holders.
Curanex Pharmaceuticals reported a net loss of $3.15 million for the three months ended March 31, 2026, sharply higher than $0.14 million a year earlier, as it ramped spending on its botanical drug pipeline.
General and administrative expenses rose to $0.93 million, while research and development reached $2.26 million, driven by IND‑enabling studies for lead candidate Phyto‑N and other programs. The company held cash and cash equivalents of $4.02 million and reported total assets of $8.41 million, with $3.91 million recorded as prepaid R&D to CROs and CDMOs.
Management concluded prior substantial doubt about going concern has been alleviated, citing IPO‑related net proceeds of roughly $15.3 million and projected liquidity for at least 12 months. Curanex advanced manufacturing and toxicology milestones for Phyto‑N, added cancer cachexia as a new core indication, but also disclosed ongoing Nasdaq minimum bid price non‑compliance that may require a reverse stock split to avoid potential delisting by November 2, 2026.
Curanex Pharmaceuticals Inc. (CURX) completed its Nasdaq IPO in August 2025, raising approximately $13.24M in net proceeds, plus $2.07M from the underwriters’ over-allotment exercise. As of September 30, 2025, the company held $5,830,537 in cash and had total assets of about $14.5M, driven largely by $8.47M of prepaid R&D with CROs and CDMOs.
The business remains pre-revenue and reported a net loss of $954,059 for the quarter and $1,151,988 for the nine months ended September 30, 2025, mainly from general and administrative costs of $466,863 and R&D expenses of $679,574. Management now concludes prior going concern doubts are alleviated based on IPO funding, though the company disclosed a Nasdaq notice on November 5, 2025 for its share price being below $1.00, with a compliance period through May 4, 2026.